Based on 2 analysts giving stock ratings to Kairos Pharma Ltd in the past month.
In the current month, KAPA has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KAPA average Analyst price target in the last month is 49.000.
Based on analysts' estimates, KAPA EPS is projected to reach -0.630 in FY2026Q4, following reported EPS of -0.592 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.59, while Kairos Pharma LtdKAPA's earnings per share (EPS) for the previous quarter was USD -0.45. EPS for the next quarter is expected at USD -0.63.